Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
BusinessWeek September 22, 2003 Faith Arner	When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool June 22, 2005 Stephen D. Simpson	Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it.
The Motley Fool January 12, 2006 Stephen D. Simpson	The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.
BusinessWeek October 9, 2006	Boston Scientific's Double Bypass First, quality problems with its defibrillators. Now, doubts about the safety of Boston Scientific's coated stents
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool May 27, 2004 Jeff Hwang	Guidant's Stent Stumble Yesterday, Guidant said that a regulatory filing for marketing approval of its Champion stainless steel stent could be delayed up to six months due to "issues" that may result in "manufacturing process modifications and/or stent design changes."
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool July 13, 2004 Jeff Hwang	J&J Weathers Stent Duel The medical device and diagnostics business Johnson & Johnson delivers a solid second quarter despite competition from Boston Scientific's Taxus stent.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool March 22, 2004 Seth Jayson	Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers?
The Motley Fool January 13, 2006 Stephen D. Simpson	Once More With Guidant In the ongoing game of tit-for-tat, Boston Scientific ups its bid for Guidant. This battle will ultimately be decided by the 800-pound gorilla that is J&J. Investors, take note.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool December 6, 2007 Brian Orelli	An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
The Motley Fool July 19, 2004 W.D. Crotty	Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific?
BusinessWeek April 23, 2007 Arlene Weintraub	Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them.
The Motley Fool November 3, 2005 Stephen D. Simpson	The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific.
The Motley Fool May 25, 2005 Stephen D. Simpson	Stent Wars 2: The Market-Share Menace The battle for drug-coated stent market share between Johnson & Johnson and Boston Scientific may not be as exciting as watching Obi-Wan Kenobi and Anakin Skywalker fight, but the outcome matters for investors.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
BusinessWeek October 9, 2006 John Carey	"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots.
The Motley Fool November 15, 2005 Stephen D. Simpson	Guidant, J&J Kiss and Make Up The two companies hammered out a revised merger agreement that continues J&J's buyout of Guidant, but at a lower price. So what does this mean for the med-tech space, assuming that this deal actually goes through? Investors, take note.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
BusinessWeek April 17, 2006 Amy Barrett	J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock.
The Motley Fool November 7, 2005 Stephen D. Simpson	All's Not Lost at Guidant Eroding sales, a partner with cold feet, and all sorts of litigation and investigation cloud Guidant's skies. Investors, take note.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
Managed Care July 2003 Thomas Morrow	Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?